

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

- 1                   1 (currently amended): A method for identifying a compound that modulates T lymphocyte activation, the method comprising the steps of:
  - 3                   (i) contacting the compound with a TRAC1 polypeptide, wherein the polypeptide comprises an amino acid sequence having at least about 90% identity to ~~an~~ the amino acid sequence of SEQ ID NO:1, wherein the TRAC1 polypeptide has ligase activity; and
  - 6                   (ii) determining the functional effect of the compound upon the TRAC1 polypeptide activity.
- 1                   2 (original): The method of claim 1, wherein the functional effect is measured *in* *vitro*.

3-5 (cancelled)

- 1                   6 (currently amended): The method of claim 1, wherein the polypeptide is heterologous and expressed in a host cell.

7-8 (cancelled)

- 1                   9 (original): The method of claim 6, wherein the host cell is primary T lymphocyte.

- 1                   10 (original): The method of claim 6, wherein the host cell is a cultured T cell.

- 1                   11 (original): The method of claim 10, wherein the host cell is a Jurkat cell.

1               12 (currently amended): The method of claim 8 1, wherein the chemical or  
2 phenotypic functional effect is determined by measuring CD69 expression, intracellular Ca<sup>2+</sup>  
3 mobilization, Ca<sup>2+</sup> influx, ligase activity, or lymphocyte proliferation.

1               13 (original): The method of claim 1, wherein modulation is inhibition of T  
2 lymphocyte activation.

1               14 (original): The method of claim 1, wherein the polypeptide is recombinant.

1               15 (original): The method of claim 1, wherein the TRAC1 polypeptide  
2 comprises an amino acid sequence of SEQ ID NO:1

1               16 (original): The method of claim 1, wherein the TRAC1 polypeptide is  
2 encoded by a nucleic acid comprising a nucleotide sequence of SEQ ID NO:2.

1               17 (withdrawn): The method of claim 1, wherein the compound is an antibody.

1               18 (withdrawn): The method of claim 1, wherein the compound is an antisense  
2 molecule.

1               19 (withdrawn): The method of claim 1, wherein the compound is a small  
2 organic molecule.

1               20 (withdrawn): The method of claim 1, wherein the compound is a peptide.

1               21 (withdrawn): The method of claim 20, wherein the peptide is circular.

1               22 (withdrawn): A method for identifying a compound that modulates T  
2 lymphocyte activation, the method comprising the steps of:  
3               (i) contacting a T cell comprising a TRAC1 polypeptide or fragment thereof with  
4               the compound, the TRAC1 polypeptide or fragment thereof encoded by a nucleic acid that

5 hybridizes under stringent conditions to an antisense nucleic acid corresponding to a nucleic acid  
6 encoding a polypeptide having an amino acid sequence of SEQ ID NO:1; and

7 (ii) determining the chemical or phenotypic effect of the compound upon the cell  
8 comprising the TRAC1 polypeptide or fragment thereof, thereby identifying a compound that  
9 modulates T lymphocyte activation.

1 23 (withdrawn): A method for identifying a compound that modulates T  
2 lymphocyte activation, the method comprising the steps of:

3 (i) contacting the compound with a TRAC1 polypeptide or a fragment thereof, the  
4 TRAC1 polypeptide or fragment thereof encoded by a nucleic acid that hybridizes under  
5 stringent conditions to an antisense nucleic acid corresponding to a nucleic acid encoding a  
6 polypeptide having an amino acid sequence of SEQ ID NO:1;

7 (ii) determining the physical effect of the compound upon the TRAC1  
8 polypeptide; and

9 (iii) determining the chemical or phenotypic effect of the compound upon a cell  
10 comprising the TRAC1 polypeptide or fragment thereof, thereby identifying a compound that  
11 modulates T lymphocyte activation.

1 24 (withdrawn): A method for identifying a compound capable of interfering  
2 with binding of an TRAC1 polypeptide or fragment thereof, the method comprising the steps of:

3 (i) combining an TRAC1 polypeptide or fragment thereof with an E2 ubiquitin-  
4 conjugating enzyme polypeptide and the compound, wherein the TRAC1 polypeptide or  
5 fragment thereof is encoded by a nucleic acid that hybridizes under stringent conditions to a  
6 nucleic acid encoding a polypeptide having an amino acid sequence of SEQ ID NO:1; and

7 (ii) determining the binding of the TRAC1 polypeptide or fragment thereof to the  
8 E2 ubiquitin-conjugating enzyme polypeptide.

1 25 (withdrawn): The method of claim 24, wherein the TRAC1 polypeptide or  
2 fragment thereof has ligase activity.

1                   26 (withdrawn): The method of claim 24, wherein the E2 ubiquitin-conjugating  
2 enzyme polypeptide is selected from the group consisting of Ubc5, Ubc7, and Ubc8.

1                   27 (withdrawn): The method of claim 24, wherein the TRAC1 polypeptide or  
2 fragment thereof and the E2 ubiquitin-conjugating enzyme polypeptide are combined first.

1                   28 (withdrawn): The method of claim 24, wherein the reaction is performed in  
2 vitro.

1                   29 (withdrawn): The method of claim 24, wherein the TRAC1 polypeptide or  
2 fragment thereof and the E2 ubiquitin-conjugating enzyme polypeptide are expressed in a cell.

1                   30 (withdrawn): The method of claim 29, wherein the cell is a yeast cell.

1                   31 (withdrawn): The method of claim 30, wherein the TRAC1 polypeptide or  
2 fragment thereof is fused to a heterologous polypeptide.

1                   32 (withdrawn): The method of claim 24, wherein the binding of the TRAC1  
2 polypeptide or fragment thereof to the E2 ubiquitin-conjugating enzyme polypeptide is  
3 determined by measuring reporter gene expression.

1                   33 (withdrawn): An isolated complex comprising a TRAC1 polypeptide or  
2 fragment thereof bound to an E2 ubiquitin-conjugating enzyme polypeptide, wherein the TRAC1  
3 polypeptide or fragment thereof is encoded by a nucleic acid that hybridizes under stringent  
4 conditions to a nucleic acid encoding a polypeptide having an amino acid sequence of SEQ ID  
5 NO:1.

1                   34 (withdrawn): The complex of claim 33, wherein the E2 ubiquitin-conjugating  
2 enzyme polypeptide is selected from the group consisting of Ubc5, Ubc7, and Ubc8.

1           35 (withdrawn): A method of modulating T lymphocyte activation in a subject,  
2 the method comprising the step of administering to the subject a therapeutically effective amount  
3 of a compound identified using the method of claim 1.

1           36 (withdrawn): The method of claim 35, wherein the subject is a human.

1           37 (withdrawn): The method of claim 35, wherein the compound is an antibody.

1           38 (withdrawn): The method of claim 35, wherein the compound is an antisense  
2 molecule.

1           39 (withdrawn): The method of claim 35, wherein the compound is a small  
2 organic molecule.

1           40 (withdrawn): The method of claim 35, wherein the compound is a peptide.

1           41 (withdrawn): The method of claim 40, wherein the peptide is circular.

1           42 (withdrawn): The method of claim 35, wherein the compound inhibits T  
2 lymphocyte activation.

1           43 (withdrawn): A method of modulating T lymphocyte activation in a subject,  
2 the method comprising the step of administering to the subject a therapeutically effective amount  
3 of a TRAC1 polypeptide, the polypeptide encoded by a nucleic acid that hybridizes under  
4 stringent conditions to a nucleic acid encoding a polypeptide having an amino acid sequence of  
5 SEQ ID NO:1.

1           44 (withdrawn): The method of claim 43, wherein the TRAC1 polypeptide  
2 comprises an amino acid sequence of SEQ ID NO:1.

1                  45 (withdrawn): A method of modulating T lymphocyte activation in a subject,  
2 the method comprising the step of administering to the subject a therapeutically effective amount  
3 of a nucleic acid encoding a TRAC1 polypeptide, wherein the nucleic acid hybridizes under  
4 stringent conditions to a nucleic acid encoding a polypeptide having an amino acid sequence of  
5 SEQ ID NO:1.

1                  46 (withdrawn): The method of claim 45, wherein the TRAC1 nucleic acid  
2 comprises a nucleotide sequence of SEQ ID NO:2.

1                  47 (new): The method of claim 1, wherein the TRAC1 polypeptide comprises an  
2 amino acid sequence having at least about 95% identity to an amino acid sequence of SEQ ID  
3 NO:1.